# A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

Source: https://onco.cc/trials/nct07460375/  
OnCo record `nct07460375` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of LCB02A in advanced solid tumours, run by LigaChem Biosciences, Inc., now recruiting.

## Summary

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07460375 by LigaChem Biosciences, Inc., with 191 participants planned, started 2026-08 and due to reach its primary completion in 2030-02. Interventions recorded: LCB02A.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07460375
- Phase: 1/2
- Setting: A First-in-Human Phase 1/2, Dose Escalation and Dose Expansion Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of Claudin18.2 (CLDN18.2)-Directed Antibody-Drug Conjugate (ADC) LCB02A in Patients With CLDN18.2-positive Advanced Solid Tumors
- Sponsor: LigaChem Biosciences, Inc.
- Enrolled: 191

## Sources

- ClinicalTrials.gov NCT07460375: https://clinicaltrials.gov/study/NCT07460375

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [LCB02A](https://onco.cc/drugs/lcb02a/)
- companies: [LigaChem Biosciences](https://onco.cc/companies/ligachem-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct07460375.json